Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer.

"Author LK has the following disclosures: Honoraria for speaker duties from Bayer.: Author JB has no disclosures.: Author MH acknowledges grant support from AAA/Novartis, ANSTO, Bayer, Isotopia. Consulting fees for lectures or advisory boards from Astellas, AstraZeneca, Janssen, Merck/MSD, Mundipharma and Point Biopharma.: Author AA has the following disclosures (lifetime): Consultant—Astellas, Janssen, Novartis, Aculeus Therapeutics; Speakers Bureau—Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb, Merck Serono, Bayer; Honoraria—Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm, Merck Sharpe Dome, Aculeus Therapeutics; Scientific Advisory Board—Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen, Noxopharm; Travel + Accommodation—Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar, Pfizer; Research Funding—Astellas (investigator), Merck Serono (investigator), Astra Zeneca (investigator), Bristol Myers Squibb (institutional), Astra Zeneca (institutional), Aptevo Therapeutics (institutional), Glaxo Smith Kline (institutional), Pfizer (institutional), MedImmune (institutional), Astellas (institutional), SYNthorx (institutional), Bionomics (institutional), Sanofi Aventis (institutional), Novartis (institutional), Ipsen (institutional), Exelixis (institutional), Merck Sharpe Dome (institutional), Janssen (institutional), Eli Lilly (institutional), Gilead Sciences (institutional), Merck Serono (institutional), Hinova (institutional)."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: LK is supported by a Vincent Fairfax Family Foundation Research Entry Scholarship from the RACP Foundation. LK and JB are both supported by a University of Melbourne Australian Government Research Training Program Scholarship. MH and AA are supported by NHMRC Investigator Grants. MH acknowledges philanthropic/government grant support from the Prostate Cancer Foundation (PCF) funded by CANICA Oslo Norway and the Peter MacCallum Foundation."